Abstract
Purpose
To report the results of long-term topical treatment with bevacizumab (Avastin) 5 mg/mL eyedrops in a case of aniridia-related neovacularization of the cornea.
Methods
Interventional case report. A female patient with aniridia had a decrease in the best corrected visual acuity from 0.32 to 0.02 in the OS over the course of 4 years, secondary to central corneal neovascularization and epithelial breakdown. Vision in the OD was 0.2. In 2008, at age 28, a shared decision was made to start off-label treatment with bevacizumab eyedrops 0.5% in both eyes. After 9 years, the visual acuity in the OD remained stable, with stability of the macropannus and maintenance of central corneal clarity. In the OS, the central corneal neovascularization regressed, the epithelium regained its clarity, and after cataract surgery visual acuity was regained to 0.32.
Results
After 9 years of treatment with topical bevacizumab, vision acuity is comparable to the situation of 12 years previously: Visual acuity remained stable in the ODS.
Conclusion
In a young patient with progressive corneal neovascularization secondary to aniridia, stability of central corneal neovascularization was obtained and corneal clarity was preserved by adding a daily drop of bevacizumab 5 mg/mL. No adverse events occurred. Vessel growth was inhibited, and as such, the progression of the natural history of the patient’s disease was halted. More clinical study with longer follow-up is needed to investigate the applicability of treatment with topical VEGF inhibitors in aniridia.
This is a preview of subscription content, log in via an institution to check access.
References
Nelson LB, Spaeth GL, Nowinski TS, Margo CE, Jackson L (1984) Aniridia. A review. Surv Ophthalmol. 28(6):621–642
Tiller AM, Odenthal MT, Verbraak FD, Gortzak-Moorstein N (2003) The influence of keratoplasty on visual prognosis in aniridia: a historical review of one large family. Cornea 22(2):105–110
de la Paz MF, Alvarez de Toledo J, Barraquer RI, Barraquer J (2008) Long-term visual prognosis of corneal and ocular surface surgery in patients with congenital aniridia. Acta Ophthalmol 86(7):735–740
Ambati BK, Nozaki M, Singh N et al (2006) Corneal avascularity is due to soluble VEGF receptor-1. Nature 443(7114):993–997
Braithwaite T, Nanji AA, Greenberg PB (2010) Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion. Cochrane Database Syst Rev 10:CD007325
Vedula SS, Krzystolik MG (2008) Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2:CD005139
Virgili G, Parravano M, Menchini F, Brunetti M (2012) Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. Cochrane Database Syst Rev 12:CD007419
Bock F, Konig Y, Kruse F, Baier M, Cursiefen C (2008) Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 246(2):281–284
Bock F, Onderka J, Rummelt C et al (2009) Safety profile of topical VEGF neutralization at the cornea. Invest Ophthalmol Vis Sci 50(5):2095–2102
Kasetsuwan N, Reinprayoon U, Satitpitakul V (2015) Prevention of recurrent pterygium with topical bevacizumab 0.05% eye drops: a randomized controlled trial. Clin Ther 37(10):2347–2351
Lekhanont K, Patarakittam T, Thongphiew P, Suwan-apichon O, Hanutsaha P (2012) Randomized controlled trial of subconjunctival bevacizumab injection in impending recurrent pterygium: a pilot study. Cornea 31(2):155–161
Wu PC, Kuo HK, Tai MH, Shin SJ (2009) Topical bevacizumab eyedrops for limbal–conjunctival neovascularization in impending recurrent pterygium. Cornea 28(1):103–104
Koenig Y, Bock F, Horn F, Kruse F, Straub K, Cursiefen C (2009) Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 247(10):1375–1382
Ihnatko R, Eden U, Lagali N, Dellby A, Fagerholm P (2013) Analysis of protein composition and protein expression in the tear fluid of patients with congenital aniridia. J Proteomics 94:78–88
Bock F, Onderka J, Dietrich T et al (2007) Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 48(6):2545–2552
Manzano RP, Peyman GA, Khan P et al (2007) Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol 91(6):804–807
Asena L, Akova YA, Cetinkaya A, Kucukerdonmez C (2013) The effect of topical bevacizumab as an adjunctive therapy for corneal neovascularization. Acta Ophthalmol 91(3):e246–e248
Galor A, Yoo SH (2010) Corneal melt while using topical bevacizumab eye drops. Ophthalmic Surg Lasers Imaging 9:1–3
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Dr. Lapid is a consultant for Alcon (USA), Eye-Yon (Israel), Hanita lenses (Israel) and Taiho Oncology (Japan), a speaker for Alcon, Hanita lenses, Santen and Thea Pharma (Belgium). Drs. Lapid and van der Meulen are clinical investigators for Alcon (USA) and ODAK (UK).
Ethical approval
The retrospective case report was exempt from IRB review and approval.
Informed consent
The patient gave full consent to the anonymized publication.
Rights and permissions
About this article
Cite this article
Lapid-Gortzak, R., Santana, N.T.Y., Nieuwendaal, C.P. et al. Topical bevacizumab treatment in aniridia. Int Ophthalmol 38, 1741–1746 (2018). https://doi.org/10.1007/s10792-017-0605-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10792-017-0605-4